about
Daclizumab for relapsing remitting multiple sclerosisDaclizumab for relapsing remitting multiple sclerosisDaclizumab for relapsing remitting multiple sclerosisDaclizumab for relapsing remitting multiple sclerosisReview of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosisDiagnosis and Management of Multiple Sclerosis in ChildrenThe efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.Promising treatments of tomorrow for multiple sclerosis.Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumabSafety of monoclonal antibodies for the treatment of multiple sclerosis.Disease-modifying therapy of pediatric multiple sclerosis.Treating multiple sclerosis with monoclonal antibodies: a 2010 update.Treatment of multiple sclerosis: current concepts and future perspectives.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.Daclizumab.Medication Treatment in Multiple SclerosisA novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis
P2860
Q24200496-447672F8-E86B-46E5-BB81-F537CF5A370EQ24201637-E32D7361-EA29-4A7C-9684-66D5A9820C36Q24234794-3379AF73-D380-42CF-9081-01287263A706Q24240947-7F423386-F5D7-4848-A3BB-A5B041279D3DQ27693249-CBA5958E-F6C5-421E-BF44-1798E8746585Q28069571-C3872C29-5A21-459F-988B-45AF83681EE0Q30730505-18D636AE-D699-46BE-A896-2FDE85EBBC46Q33670947-0A9B8BA8-3D64-4017-9832-CA01F6F60750Q33707389-BF75C205-A49C-4CDA-B0FF-17A953E82FA1Q34542922-08BA748A-3289-4439-A5A5-CCFE6DA75504Q36568645-51C4F6B4-F13B-4A0C-A552-FD7375174CD9Q37737305-68EEB669-F79E-49CF-8A5C-343452222358Q37884434-25D7E528-9564-47AC-89E5-9ABED2FB677CQ37968620-52559D6E-F610-4425-B8A9-0357D281E5F0Q38397484-FA90A9D6-906E-4872-B0C3-FED2746EB37CQ43905322-F1BB74D9-C9F5-4125-BA75-73FD79744E54Q46487963-9BDF2235-A6D6-4372-8849-6B2684B58395Q57083576-A02155D4-456E-414F-B96D-44395F496108Q57430578-1D3A7ECB-FD3B-4BCE-8011-5977134DF170
P2860
description
im Oktober 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 09 January 2009
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2008
@uk
name
Daclizumab in treatment of multiple sclerosis patients
@en
Daclizumab in treatment of multiple sclerosis patients
@nl
type
label
Daclizumab in treatment of multiple sclerosis patients
@en
Daclizumab in treatment of multiple sclerosis patients
@nl
prefLabel
Daclizumab in treatment of multiple sclerosis patients
@en
Daclizumab in treatment of multiple sclerosis patients
@nl
P2093
P2860
P356
P1476
Daclizumab in treatment of multiple sclerosis patients
@en
P2093
P2860
P304
P356
10.1177/1352458508097468
P50
P577
2009-01-09T00:00:00Z